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ARTICLE

Association analysis of copy numbers of FC-gamma
receptor genes for rheumatoid arthritis and other
immune-mediated phenotypes
Lude Franke1,14, Hanane el Bannoudi2,14, Diahann TSL Jansen2, Klaas Kok1, Gosia Trynka3,4,5,
Dorothee Diogo3,4,5, Morris Swertz1,6, Karin Fransen1,7, Rachel Knevel2, Javier Gutierrez-Achury1,
Lisbeth Ärlestig8, Jeffrey D Greenberg9, Joel Kremer10, Dimitrios A Pappas11, Alexandros Kanterakis1,6,
Rinse K Weersma7, Annette HM van der Helm-van Mil2, Viktor Guryev12, Solbritt Rantapää-Dahlqvist8,
Peter K Gregersen13, Robert M Plenge3,4,5, Cisca Wijmenga1, Tom W-J Huizinga2, Andreea Ioan-Facsinay2,
Rene EM Toes2,15 and Alexandra Zhernakova*,1,2,15
Segmental duplications (SDs) comprise about 5% of the human genome and are enriched for immune genes. SD loci often show
copy numbers variations (CNV), which are difﬁcult to tag with genotyping methods. CNV in the Fcγ receptor region (FCGR) has
been suggested to be associated with rheumatic diseases. The objective of this study was to delineate association of FCGR-CNV
with rheumatoid arthritis (RA), coeliac disease and Inﬂammatory bowel disease incidence. We developed a method to accurately
quantify CNV in SD loci based on the intensity values from the Immunochip platform and applied it to the FCGR locus. We
determined the method’s validity using three independent assays: segregation analysis in families, arrayCGH, and whole genome
sequencing. Our data showed the presence of two separate CNVs in the FCGR locus. The ﬁrst region encodes FCGR2A, FCGR3A
and part of FCGR2C gene, the second encodes another part of FCGR2C, FCGR3B and FCGR2B. Analysis of CNV status in 4578
individuals with RA and 5457 controls indicated association of duplications in the FCGR3B gene in antibody-negative RA
(P = 0.002, OR = 1.43). Deletion in FCGR3B was associated with increased risk of antibody-positive RA, consistently with
previous reports (P = 0.023, OR = 1.23). A clear genotype–phenotype relationship was observed: CNV polymorphisms of the
FCGR3A gene correlated to CD16A expression (encoded by FCGR3A) on CD8 T-cells. In conclusion, our method allows
determining the CNV status of the FCGR locus, we identiﬁed association of CNV in FCGR3B to RA and showed a functional
relationship between CNV in the FCGR3A gene and CD16A expression.
European Journal of Human Genetics (2016) 24, 263–270; doi:10.1038/ejhg.2015.95; published online 13 May 2015

INTRODUCTION
Segmental duplications (SDs) are loci with two or more, highly
similar, duplicated regions. These loci cover about 5% of the human
genome and are enriched for immune-mediated genes.1,2 One of the
SDs encodes the low-afﬁnity human FC-gamma receptors (FcγR).
FcγR are glycoproteins that bind the Fc region of IgG and have a
pivotal role in many immunological processes.3–8 FcγR are expressed
by various immune cell types and provide a critical link between the
humoral and the cellular compartments of the immune system. The
proteins encoded by FCGR genes (CD16, encoded by FCGR3, and
CD32, encoded by FCGR2) are cell surface receptors that are involved
in the process of phagocytosis and the clearing of immune complexes.

Genetic analysis of the FCGR locus in genome-wide association studies
(GWAS) has been limited, because genes encoding the FcγR molecules
are located in highly homologous SD blocks. The low-afﬁnity FCGR
gene family is located in blocks of two repeats of ~ 82 kb with 498%
being identical. It includes three FCGR2 genes (FCGR2A (CD32A),
FCGR2B (CD32B) and FCGR2C (CD32C)) and two FCGR3 genes
(FCGR3A (CD16A) and FCGR3B (CD16B)). The genetic structure of
the low-afﬁnity FCGR gene family in relation to blocks of SD is
presented in Figure 1a–c.
Because of the complex genetic structure of the FCGR locus, only
the promoter and the ﬁrst three exons of the FCGR2A gene are tagged
by genetic variants present on current genome-wide genotyping
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Figure 1 The genetic structure of the FCGR locus. The genetic structure of the low-afﬁnity FCGR gene family in relation to blocks of SD and LD in the locus.
The LD block is constructed based on analysis of 43 single-nucleotide polymorphisms that passed quality control and had MAF45% in Dutch RA and
control cohorts.

platforms. SNPs in the FCGR2A gene (outside the SD locus) are
strongly associated with inﬂammatory bowel disease (IBD) and in
particular to its subgroup ulcerative colitis (UC).9,10 Less strong
association was reported with systemic lupus erythematosus (SLE)
(rs1801274:A4G, P = 6.78 × 10 − 7)11 and rheumatoid arthritis (RA)
(rs12746613:C4T, P = 2 × 10 − 5).12 The exact genetic risk of the
whole locus contributing to disease is unknown and cannot be
assessed by GWAS. However, several reports of deletions and
duplications of FcγR genes have been published.13–18 The relevance
of copy number variants (CNV) in the FcγR locus in SLE has been
strongly suggested by several studies,4,15,18–21 whereas similar analyses
in RA showed contradictory results.18
At least four experimental techniques have been proposed to
quantify copy numbers within this SD. These include quantitative
PCR,19 comparative genomic hybridization (arrayCGH),22 multiplex
ligand-dependent probe ampliﬁcation23 and several variations of
paralogous ratio tests (PRT), including the use of PRT in combination
with quantitative sequence variant (QSV) assay.17,24 However, none of
these methods provides an accurate estimation of both the number
and location of CNVs. Methods based on quantitative PCR give a
continuous, rather than discrete, value of CNVs (reviewed in
McKinney et al18). Other methods aim to design sets of primers and
probes speciﬁc to the FCGR3A or FCGR3B genes, which is a
complicated task given the high homology of these genes. The PRT
method, including the genotyping of a reference diploid sequence on
chromosome 18, is probably the most robust reported to date,24 but it
European Journal of Human Genetics

does not allow identiﬁcation of CNV boundaries. Recently, the
combination of a PRT probe with QSV was applied to an RA case–
control analysis, allowing an estimation of CNV in 1115 RA patients
and 654 controls.17 This study suggested that there is an association
with lower CNV in the FCGR3B gene in RA patients.
The Immunochip is an Illumina array, which includes SNPs to ﬁne
map 186 distinct loci associated with at least 1 of the 12 immunemediated diseases, including RA, CeD and IBD.9,25–28 The low-afﬁnity
FcγR locus is also included in the Immunochip platform for ﬁnemapping. The Immunochip was not speciﬁcally designed to quantify
CNVs, as its primary focus was on calling bi-allelic SNP genotypes.
Previously, several methods of quantifying CNV changes based on
intensity values of genotyping probes have been proposed.29–37 As
these methods rely upon raw intensity measures, it is crucial to
properly account for any systematic differences that may exist (eg,
batch effects), which is especially important when comparing many
thousands of samples that have been hybridized in different laboratories. In this study, we developed a highly robust method to
accurately quantify FCGR-CNV using the Immunochip, by extensively
correcting for various confounders through principal component
analysis (PCA). We conﬁrmed our results using three independent
methods (segregation analysis in families, arrayCGH and nextgeneration sequencing (NGS) analysis) and then applied our method
to a cohort of 4578 RA patients as well as 5235 individuals with two
other immune-mediated diseases (CeD and IBD) and 7941 controls.
We identiﬁed association of CNVs in FCGR3B in RA. Functional
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analysis showed that copy numbers in the FCGR locus have a clear
effect on the expression of FcγRs in major blood cell types.
MATERIALS AND METHODS
Sample collection
After quality control, our sample collection included 4578 RA cases from three
populations (the Netherlands, Sweden and the USA), 1477 IBD samples (900
CD and 577 UC, all from the Netherlands), 3758 CeD cases from ﬁve
populations (the Netherlands, Poland, Spain, Italy and India) and 7941
matched population controls. In total, 17 754 samples were included in the
case–control analysis. In addition, 285 offspring from the Genome of the
Netherlands (GoNL, www.nlgenome.nl)38 were included for segregation
analysis, giving a total of 18 039 individuals (Table 1). Written informed
consent was obtained from all subjects; the research was approved by the ethics
committee or institutional review boards of all the participating institutions.

SNP genotyping
Samples were genotyped using the Immunochip according to Illumina’s
(San Diego, CA, USA) protocols at ﬁve laboratories (listed in Supplementary
Methods). The ﬁnal report ﬁle, including R intensity values, was extracted for
all FCGR and reference SNPs, as listed in Supplementary Table S1.

Data quality control
The Illumina GenomeStudio GenTrain2.0 algorithm was used to cluster
samples. Only samples with call rates 499% that also passed the QC for the
primary Immunochip analysis in each disease (described in Jostins et al,9 Eyre
et al25 and Trynka et al26) were included. We performed an extra check to
exclude any duplicates or ﬁrst-degree relatives in the combined analysis.

FCGR copy number count quantiﬁcation
The algorithm for CNV estimation is described in detail in the Supplementary
Methods section.

Identiﬁcation of CNVs by arrayCGH
In 22 individuals, the complete FCGR locus was assessed by a dense set of
arrayCGH probes, using a custom-designed array (Agilent, Santa Clara, CA,
USA; ID 029465). In total, 2704 arrayCGH probes were included in the
extended FcγR locus, of which 1171 were located in the SD (see Supplementary
Methods for further details).

Sequencing analysis
We selected 20 individuals with various combinations of CNVs in blocks 1 and
2 from the GoNL study,38 for whom, on average, 14x whole genome sequences
were made and Immunochip SNP genotypings were available. We predicted
their CNV status using a dynamic window approach (DWAC-Seq, http://tools.
genomes.nl/dwac-seq.html)), see Supplementary Methods for details.

Statistical analysis
CNV quantiﬁcation was performed using the customized Java software
(available at https://github.com/molgenis/systemsgenetics/wiki/Copy-numberdetermination-using-ImmunoChip-intensity-data-for-the-FCGR-locus.
Association analysis was done by chi-square testing using SPSS (Armonk,
NY, USA) and R. Correlation of genotypes and expression of the protein was
performed in SPSS v19. Meta-analysis was performed using an inverse variance
meta-analysis using R. Power calculations were performed using http://pngu.
mgh.harvard.edu/~purcell/gpc/. The Breslow–Day test for genetic heterogeneity
was performed using R. The haplotype analysis was done using Haploview,39
default settings.

Functional studies
To stain CD16 molecules on different cell types, fresh leukocytes were isolated
from the blood of 21 healthy individuals using HetaSep (StemCell Technologies, Vancouver, BC, Canada). Cells were stained with antibodies against CD3,
CD4, CD8, CD14, CD16 and CD19.
To identify which isoform of CD16 (CD16a or CD16b) was expressed on
CD8+ cells, leukocytes were left untreated or were treated with 5 U/ml
phosphatidylinositol-speciﬁc phospholipase C (PI-PLC) for 1 h at 37 °C under
constant mixing. After extensive washing, cells were stained with antibodies

Table 1 Sample collection
Population

Controls (% females)

Cases (% females)

CCPpos (% females)

CCPneg (% females)

CCPunkn

Total

RA cohort
NL

1379 (44%)

648 (67%)

332 (67%)

300 (66%)

16

2027

SW
US_NY

942 (68%)
1275 (69%)

675 (68%)
2238 (74%)

406 (67%)
1567 (74%)

190 (65%)
531 (76%)

79
140

1617
3513

US_B
Total

1861 (75%)
5457

1017 (79%)
4578

1006 (79%)
3311

0
1021

11
246

2878
10 035

Population

Controls (% females)

Cases (% females)

Total

1379 (44%)
1255 (81%)

1110 (68%)
1374 (67%)

2489
2629

Poland
Spain

532 (42%)
306 (53%)

505 (63%)
545 (68%)

1037
851

India
Total

391 (16%)
3863

224 (55%)
3758

615
7621

Controls (% females)

IBD cases (% females)

CrD (% females)

UC (% females)

Total

1379 (44%)

1548 (65%)

900 (65%)

577 (48%)

2927

Controls

Cases

Family members

All samples

7941

9813

285

18 039

Coeliac disease
NL
Italy

Population
IBD
NL
All study
Total
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against CD3, CD8, CD15 and CD16 − or an irrelevant isotype-matched
antibody for 20 min at 4 °C. The expression of CD16 on CD8+ T cells, and
neutrophils was assessed by FACS. Detailed information is described in
Supplementary Methods.

Data sharing
The results of this study are submitted to DGVArchive (http://www.ebi.ac.uk/
dgva/data-download), submission number estd222.

RESULTS
Haplotype structure of the FCGR locus
To gain insight into the haplotype structure of the FCGR locus, we ﬁrst
investigated the Immunochip Genome Studio cluster plots for 1159
SNPs located in the block of SD in Dutch RA cases and controls. Only
114 SNPs (9.8%) passed our quality criteria for SNP genotyping (minor
allele frequency (MAF)40.1%, Hardy Weinberg equilibrium (HWE)
P-value40.0001). Of these, 75 SNPs (6.5%) had a MAF41%, while
only 43 SNPs (3.7%) passed the quality criteria with a MAF45%.
Haplotype analyses on SNPs with MAF45% showed strong linkage
disequilibrium (LD) across the whole locus but identiﬁed two LD
blocks. The split between the two blocks (D’ = 0.68) corresponded
approximately to the split between the two duplicated regions
(Figure 1a–c). As the two CNV blocks included the complete sequence
of the FCGR3A gene (left block) and the FCGR3B gene (right block),
respectively, we will refer to these as the FCGR3A and FCGR3B CNV
loci, although the borders of both CNVs are wider than the FCGR3A
or 3B genes (see Figure 1a–c).
Visual inspection of all 1159 SNP clusters clearly indicated the
presence of several SNPs with a CNV pattern (ie, more than three
clusters were visible per SNP, see Supplementary Figure S1). In total,
at least 13 SNPs with a CNV pattern were located in the FCGR3A
block, and at least 11 SNPs showed a CNV pattern in the FCGR3B
block (Supplementary Tables S2 and S3). Next, we developed an
algorithm to estimate CNV in the FCGR locus based on analysing the
ﬂuorescent dye intensities of multiple SNPs genotyped on the Illumina
Immunochip platform, as described in the Supplementary Methods.
We performed the analysis of CNVs in the FCGR locus in three
ways: (1) All 1159 SNPs were included, indicating the average number
of copies in both FCGR3A and FCGR3B blocks (Supplementary Table
S1). (2) PCA of 13 CNV-like SNPs from the FCGR3A block
(Supplementary Table S2). (3) PCA of 11 CNV-like SNPs from the
FCGR3B block (Supplementary Table S3). In all the three analyses,
the ﬁrst principal component from the PCA of the FCGR SNP
intensity data correlated the number of copies for each individual
(Supplementary Figures S2a–c). We also investigated whether any of
the ﬁrst 10 PCs from the combined analysis of all 1159 FCGR SNPs
reﬂected the CNV status of FCGR3A and/or FCGR3B blocks, and we
found that the third PC does correspond to the CNV status of the
FCGR3A block. Consistent with this observation, of the 100 top SNPs
that explain most of the third PC, 97 are annotated in the FCGR3A
block. Combining the ﬁrst and third PCs from the 1159 SNP analysis
showed the clearer cluster separations in all populations, concordant
with the results obtained by analysing the FCGR3A and FCGR3B
blocks (Figure 2). In consequence, we used this method to deﬁne the
CNV status. In both duplicated blocks, three, four and more copies
could not be undoubtfully separated from each other; they were
therefore combined in one group of ≥ 3 copies.
After estimating the CNV status for each individual, we validated
our CNV estimation algorithm by three independent methods:
segregation analysis in families, arrayCGH, and whole genome
sequencing.
European Journal of Human Genetics

Segregation in the families
We ﬁrst studied the segregation of the FCGR CNVs in 257 trio families
to verify the outcome of our new method. For the FCGR3A block, the
inferred FCGR3A CNV genotypes of the 257 trios showed perfect
Mendelian inheritance, indicating that our method correctly assigned
these genotypes. The same was also true for the FCGR3B block, except
for two unlikely events in the distribution of FCGR3B CNV, which
could occur due to recombination or uneven distribution of CNV on
parental chromosomes. The genotypes of all parent–child trios are
presented in Supplementary Table S4.
ArrayCGH analysis
We next used arrayCGH to conﬁrm the CNV quantiﬁcation yielded
by our method. We selected 22 individuals representing three different
CNVs in the FCGR3A locus (1, 2 and ≥ 3 copies), and four CNV types
in FCGR3B (0, 1, 2 and ≥ 3 copies) based on the PCA analysis. The
selection and CNV genotypes of these 22 samples are indicated in
Supplementary Table S5.
ArrayCGH analysis showed perfect correlation with the combined
number of copies of FCGR3A+FCGR3B blocks. However, the
arrayCGH method could not separate the CNVs seen in the two
blocks, not even when the analysis was performed only on probes
annotated as unique for either block. For example, individuals with a
double deletion of the FCGR3B block showed a low signal across the
whole FCGR locus (2/4 copies, Supplementary Figure S3a), while
those with a single deletion of the FCGR3B or FCGR3A block showed
a similar pattern of deletion on the whole FCGR block on arrayCGH
analysis (3/4 copies) (Supplementary Figures S3b–c). Similarly,
individuals with three copies of FCGR3A or FCGR3B showed similar
arrayCGH patterns (Supplementary Figure S3d). We concluded that
arrayCGH conﬁrmed the results of our PCA analysis but that
arrayCGH cannot be used to assess the CNV structure of the FCGR
locus accurately.
Next-generation sequencing analysis
To further conﬁrm our PCA-based method of estimating CNVs, we
compared the results with those from NGS analysis. We selected 20
individuals with various CNV distributions in the FCGR3A and
FCGR3B blocks and performed a CNV analysis of the whole genome
sequence data using DWAC-Seq. Of the 40 CNVs included for
conﬁrmation analysis, we observed a perfect match between the
results obtained by both methods (Supplementary Table S6).
Together, the results from segregation analysis, arrayCGH and
sequencing suggest that our method accurately estimates the CNV
structure in the FCGR locus.
Structural composition of the FCGR locus
We next analysed the structural composition of FCGR CNVs in the
cohort of 17 754 individuals. The FCGR3A deletion is extremely rare:
only 2 out of the 17 754 individuals carried a double deletion (0
copies) for FCGR3A, and 275 individuals (1.5%) harboured a deletion
of one FCGR3A allele. CNV in FCGR3B is more common: we
identiﬁed 46 out of the 17 754 (0.26%) individuals with double
deletion of the FCGR3B locus, whereas 1304 subjects (7.4%) had a
deletion of one copy of the FCGR3B block. There were no individuals
with a double deletion of both genes, and only 9 out of the 17 754
individuals had a single-copy deletion in both the FCGR3A and
FCGR3B loci. The frequency of CNV per population and in every
disease group is presented in Supplementary Tables S7–S9.
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Figure 2 CNV frequency distributions of the FCGR3A and FCGR3B based on PC1 and PC3 of analysis of all 1159 single-nucleotide polymorphisms in the
FCGR locus.

Association of CNV in FCGR locus with RA, IBD and CeD
We next investigated whether the CNVs in FCGR locus are associated
with RA (including the CCP+ and CCP − groups), CeD and IBD. All
analyses were performed separately per population and per disease
(Supplementary Tables S7–S9) and then combined in a meta-analysis
(Supplementary Table S10, Figure 3). We did not observe strong
heterogeneity across populations (calculated by Breslow–Day test,
Supplementary Table S11).
No signiﬁcant association, in any group, was observed with
deletions or duplications of FCGR3A block. Given the low frequency
of FCGR3A deletions, it should be noted that our sample size only had
sufﬁcient power to determine strong effects of this rare variant
(Supplementary Table S12).
In the FCGR3B gene, we observed associations of CCP − RA with
duplication of the FCGR3B locus, where an extra copy of the FCGR3B
block showed a susceptible effect in CCP − RA (P = 0.002, OR 1.429,

95% CI (1.146–1.782)). A similar, less signiﬁcant, trend was observed
in CeD analysis (P = 0.085, OR = 1.149, 95% CI (0.981–1.345)).
Previous studies have indicated an association with deletion of the
FCGR3B locus in CCP+ RA, although these results were
inconsistent.16–18 In our analysis, we identiﬁed nominally signiﬁcant
association with deletion of the FCGR3B locus, and the trend of
association was consistent with the previous observations (P = 0.023,
OR = 1.229, 95% CI (1.029–1.467); Figure 3 and Supplementary Table
S10). In the combined analysis of FCGR3A and FCGR3B blocks, trend
of association of high CNV with CCP − RA was observed (P = 0.004,
OR = 1.328, 95% CI (1.093–1.614)).
Overall, only association of FCGR3B duplication with CCP − RA
was signiﬁcant after correction for multiple testing (Bonferroni;
P(corr) = 0.02).
Although our method is capable of quantifying CNV in the FCGR
locus properly, it is a fairly complicated procedure, requiring raw
European Journal of Human Genetics
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Figure 3 Meta-analysis of FCGR3A, FCGR3B and FCGR3A+FCGR3B blocks in RA, CD and IBD.

intensity data of both the FCGR locus and other autosomal regions in
order to accurately correct for batch effects. A much more straightforward procedure would be possible if a normal bi-allelic SNP were
in strong LD with the FCGR3A or FCGR3B loci. We therefore
investigated whether any SNP in or around the locus could tag the
European Journal of Human Genetics

FCGR3A and/or FCGR3B CNVs. We found no SNP proxies to tag the
CNV genotype (max D’ = 1, r2o0.1) (Supplementary Figure S4); we
therefore concluded that CNV estimation algorithms need to be
applied to genotype the FCGR locus properly. Given the previous
reports of association of SNPs in the FCGR locus to RA, we have also
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investigated the association of bi-allelic SNPs with RA, including the
CCP+ and CCP − subgroup analysis. We looked for association in the
locus chr1: 160,975,205-162143863 (from 500 kb left from start of
FCGR2A till 500 kb right from end of FCGR3B gene). None of the
SNPs were associated with RA with Po0.003 (including analyses in
the CCP+ and CCP − subgroups).
Expression of CD16 in relation to CNVs in FcγR locus. To identify the
functional consequences of CNVs in FCGR3A and FCGR3B, we tested
the expression of CD16 (FcγRIII) receptor on neutrophils, monocytes,
B and T cells. Despite previous studies17,40,41 reporting a correlation
between neutrophil CD16b expression and FCGR3B copy number, we
did not observe this correlation in our own samples (Supplementary
Figure S5). However, we did observe a signiﬁcant correlation of
FCGR3A CNV and expression of CD16 on CD8+ T-cells (P-value for
correlation P = 0.0018) (Figure 4). No correlation was observed for
monocytes, B cells or CD4+ T cells. We conﬁrmed that the Fc
receptor expressed on this subtype of T cells is the CD16a form
(encoded by FCGR3A) by using PI-PLC, an enzyme that cleaves the
GPI-linked form of CD16 (ie, CD16b, encoded by FCGR3B). This
enzyme was not able to cleave CD16 from CD8+ T cells, although it
was able to cleave CD16 from neutrophils, indicating that neutrophils
carry CD16b and CD8+ T cells carry CD16a (Supplementary Figure
S6). Further characterization of CD8+CD16+T cells indicated that
they carry the αβ T-cell receptor and have a terminally differentiated
phenotype42 based on the following characterization; CD45RA
+CCR7 − CD27–CD28 − (data not shown).
DISCUSSION
The analysis of genetic association in SD loci is challenging due to
their complex genetic structure. In this study, we have developed a
method for CNV analysis in SD loci and applied it to the FCGR locus.
Our method is based on PCA of raw intensity values of SNPs in CNV
regions. We conﬁrmed our results with three independent methods:
segregation analysis in families, arrayCGH, and sequencing analysis.
We found that CNVs were segregated in families, as expected, and
there was a good correlation of the results from our method with
those from NSG analysis. We also concluded that arrayCGH method

Figure 4 Correlation of FCGR3A CNV and expression of CD16 on CD8 cells.
X-axis: different numbers of copies of FCGR3A. y Axis: percentage of
CD16+CD8+ cells.

is not accurate enough for ﬁne-mapping CNVs in the FCGR locus, as
it does not allow the speciﬁc identiﬁcation of FCGR3A and FCGR3B
CNVs. The CNV estimation from arrayCGH does, however, gives a
good correlation with the total number of copies in both the FCGR3A
and FCGR3B blocks. The boundaries of two CNV blocks identiﬁed in
this study correspond approximately to the recent ﬁndings of breakpoints of FCGR3B deletion (24.5 kb region of identity in the FCGR2C
and FCGR2B genes), identiﬁed by high-throughput sequencing
analysis.21
Association of low copies of FCGR3B with RA was recently
suggested in a study of a cohort of 1115 cases and 654 healthy
individuals (P = 0.028; OR = 1.50). This association appeared stronger
in CCP+ individuals (P = 0.011; OR = 1.61; 932 CCP+ cases
included).17 A similar trend, although not signiﬁcant, was observed
by another meta-analysis that included a comparable number of
samples (P = 0.15; OR = 1.36).18 We applied our method to a large
cohort of 17 754 individuals with immune-mediated phenotypes and
matched controls, including RA, CeD and IBD. As our study included
4578 RA patients (of which 3311 were CCP+ RA patients) and
5457 population-matched controls, we had sufﬁcient power
(Supplementary Table S12) to conﬁrm the reported association
mentioned above. We observed similar association with deletion in
FCGR3B in the CCP+ subgroup of RA (P = 0.023, OR = 1.229),
although this ﬁnding was not signiﬁcant after correction for multiple
testing. Similar results observed in three independent data sets suggest
that association of deletion of FCGR3B in CCP+ RA patients is most
likely a true-positive association and that the effect size of FCGR3B
deletion on CCP+ RA is in the range of OR 1.2–1.5. We also identiﬁed
an association in FCGR3B with the CCP − subgroup of RA, where
high CNV in FCGR3B was associated with disease (P = 0.002, OR
1.429). Overall, this indicates that CNVs in the FCGR3B locus show a
different effect on the autoantibody-positive and -negative subgroups
of RA. CCP can interact with FCGR3B leading to activation of various
immune cells and are the most speciﬁc biomarkers for RA. It is now
clear that the genetic contribution to CCP-positive and -negative
disease is different. Our observation that the contribution of CNVs in
the FCGR3B appears distinct for CCP-positive and -negative RA is in
line with these ﬁndings that also indicate that CCP-positive and
-negative disease have a different aetiology.
We did observe a signiﬁcant positive correlation of FCGR3A CNV
and the expression of CD16 on CD8+ T-cells, which has not been
reported before. Intriguingly, this correlation is not present for other
immune cells that express CD16a, indicating a cell-speciﬁc regulation
of the expression of this receptor. The role of CD8+ T-cell immunity
in RA is presently unclear, and it is not known whether CD16
expression on CD8+ T cells is involved in the inﬂammatory process
operative in RA. However, it would be interesting to know whether
the CD16 expression of CD8 T cells differs between CD8+ T cells
obtained from CCP-positive and -negative patients, as differential
expression of CD16 in these two subgroups of RA would suggest a role
for these cells in (CCP-positive) disease.
Overall, we have created a framework to identify deletions and
duplications from intensity values of SNP genotypes on genome-wide
association platforms. By conﬁrming the results from our method
with family segregation analysis, array CGH and sequencing analysis,
we have shown that they are accurate and reliable and have identiﬁed a
functional correlation between FCGR3A CNV with CD16 expression
on CD8+ T cells. Our method can now be applied to other CNVs
genotyped on the Immunochip platform or on any other dense SNP
genotyping platform.
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